Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed share issue, whereby Xspray receives gross proceeds of approximately SEK 265 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue is inter alia to enhance the company’s financial position ahead of negotiating a deal pertaining to its lead product HyNap-Dasa and to continue to expand the company’s product portfolio.

Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström, Joel Magnusson and Linnea Petersson.

Related

Vinge advisor in connection with Klarna's IPO on the New York Stock Exchange

Vinge, together with Latham & Watkins, acted as advisor to bookrunners and managers in connection with the listing of Klarna, the global digital bank and provider of flexible payment solutions, on the New York Stock Exchange.
September 15, 2025

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025